Spectrum Pharmaceuticals Announces Initiation Of Phase 2 Trial Evaluating Satraplatin In Combination With Tarceva In Patients With Lung Cancer
SpectrumPharmaceuticals, Inc. (Nasdaq: SPPI) announced today that its partner, GPCBiotech, has initiated a Phase 2 randomized trial evaluating satraplatin incombination with Tarceva(R) (erlotinib) as a first-line therapy in patientswith inoperable, advanced non-small cell lung cancer (NSCLC) who are 70years of age and older. [click link for full article]
